Kyle R Crassini

8PUBLICATIONS
22CO-AUTHORS
Language documentation and descriptionCardiology (incl. cardiovascular diseases)Humoural immunology and immunochemistryMolecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 07, 2026
Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.

|Jul 27, 2025
Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors.

Mary Ann Anderson, Farrukh T Awan, Leanne Berkahn

|Dec 09, 2023
Pathogenesis and management of immune dysfunction secondary to B cell haematological malignancies.

Kyle Crassini, John Gibson

|Jul 18, 2022
The ClpP activator ONC-212 (TR-31) inhibits BCL2 and B-cell receptor signaling in CLL.

Narjis Fatima, Yandong Shen, Kyle Crassini

|Aug 01, 2019
Molecular pathogenesis of chronic lymphocytic leukaemia.

Kyle Crassini, William S Stevenson, Stephen P Mulligan

|Jul 07, 2018
The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment.

Kyle Crassini, Yandong Shen, Michael O'Dwyer

Pageof 2

Frequent Collaborators

5 joint publications

Oliver G Best

2 joint publications

Mary Ann Anderson

2 joint publications

Constantine Tam

1 joint publications

Paula Marlton